| Dokumendiregister | Ravimiamet |
| Viit | ML-7/5246-2 |
| Registreeritud | 11.11.2026 |
| Sünkroonitud | 12.11.2026 |
| Liik | Sissetulev kiri |
| Funktsioon | ML Ravimite müügiload ja dokumentatsiooni hindamine |
| Sari | ML-7 Ravimite müügiloa alane üldine kirjavahetus |
| Toimik | ML-7/2026 |
| Juurdepääsupiirang | Avalik |
| Adressaat | European Commission |
| Saabumis/saatmisviis | European Commission |
| Vastutaja | Aet Viispert (RA, Peadirektori asetäitja valdkond, Müügilubade osakond) |
| Originaal | Ava uues aknas |
| Taotle dokumendi eemaldamist või parandamist |
Mrs Katrin Kiisk
Director-General State Agency of Medicines Estonia
Mrs Indra Dreika
Director Head of Administrative Department State Agency of Medicines Latvia
Mrs Dovilė Marcinkė
Director State Medicines Control Agency Lithuania
Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË – Tel. +32 22991111
E-mail: [email protected]
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY
Medical Products and Innovation
Medicines: Policy, Authorisation and Monitoring
Brussels SANTE.D.1/KS/am(2026)11531097
Subject: Request for the continued implementation of the electronic package
leaflet project in Estonia, Latvia and Lithuania
Dear Dr Kiisk, Ms Dreika and Ms Marcinkė,
Thank you for your joint letter of 7 October 2026 concerning the electronic package leaflet
(ePL) project in Estonia, Latvia and Lithuania, and for the constructive cooperation of your
authorities in the implementation of this initiative since its launch on 1 January 2022 and
its subsequent extension from 1 January 2024.
The Commission takes note of the positive experience reported by the Baltic medicines
agencies and of your assessment that the project has delivered practical benefits in terms
of the availability of medicinal products, reduced administrative and operational burden,
improved access to the most up-to-date authorised product information for healthcare
professionals, and environmental advantages through the reduced use of printed package
leaflets.
The experience gathered through this project is of clear interest in the broader context of
the ongoing digital transformation of product information in the Union. In particular, the
practical lessons derived from the implementation in the Baltic States may usefully
contribute to future reflections on electronic product information when implementing the
new EU Pharmaceutical Directive in the Member States and at Union level.
In light of the information provided and the positive practical experience accumulated
since 2022, the Commission agrees that the project may continue in Estonia, Latvia and
Lithuania to gain more experience and continue learning from it. The pilot will provide an
opportunity to better prepare for the transposition and implementation of new requirements
for electronic package leaflets into national legislation until the new EU Pharmaceutical
2
Directive becomes applicable. Therefore, the pilot should run without interruption until the
new Pharmaceutical Directive is implemented into national law and becomes applicable.
The Commission would be grateful if the participating authorities could continue to keep
DG SANTE informed of the implementation of the project, including any significant
developments, operational issues identified, or lessons learned that may be relevant for
broader regulatory considerations at Union level.
Thank you again for your letter and for your continued engagement on this matter.
Yours sincerely,
Olga SOLOMON
Head of Unit
Electronically signed
Electronically signed on 09/11/2026 23:36 (UTC+01) in accordance with Article 11 of Commission Decision (EU) 2021/2121
| Nimi | K.p. | Δ | Viit | Tüüp | Org | Osapooled |
|---|---|---|---|---|---|---|
| Request for the continued implementation of the electronic package leaflet (ePL) project in Estonia, Latvia and Lithuania without a predefined end date | 07.10.2026 | 36 | ML-7/5246-1 | Väljaminev kiri | ra | European Commission |